Imperial College London
Alternate

Professor Sir Steve Bloom FMedSci, FRS

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Departmental Academic REF2014 Lead
 
 
 
//

Contact

 

+44 (0)20 7594 9048s.bloom Website

 
 
//

Assistant

 

Ms Keda Price-Cousins +44 (0)20 7594 9048

 
//

Location

 

6N3Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Choudhury:2016:10.1097/MED.0000000000000216,
author = {Choudhury, SM and Tan, TM and Bloom, SR},
doi = {10.1097/MED.0000000000000216},
journal = {Current Opinion in Endocrinology Diabetes and Obesity},
pages = {18--22},
title = {Gastrointestinal hormones and their role in obesity},
url = {http://dx.doi.org/10.1097/MED.0000000000000216},
volume = {23},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Purpose of review: Pandemic obesity is the most pressing health issue of this century. The most successful treatment so far is bariatric surgery, but for various reasons, surgery cannot be applied to all patients who require treatment. Gastrointestinal hormones are likely to play a key role in the success of bariatric surgery. This article examines in detail three of these gut hormones: peptide YY, oxyntomodulin and pancreatic polypeptide, and reviews how recent developments may offer new targets for therapy.Recent findings: Both the free fatty acid 2 and the melanocortin 4 receptors have been discovered to regulate peptide YY and glucagon-like peptide-1 secretion, and drugs targeting these may represent new antiobesity therapies. Dual agonism of glucagon-like peptide-1 and glucagon receptors, for example with oxyntomodulin, has synergistic effects in reducing appetite and increasing energy expenditure. Plasma pancreatic polypeptide concentration correlates with visceral adiposity, and may serve as a biomarker for metabolic syndrome.Summary: Gut hormones continue to show promise on an individual basis as anti-obesity treatments, but combination therapies are needed to achieve beneficial effects comparable to bariatric surgery. Innovative pathways for stimulating native gut hormone secretion may well provide an alternative method for weight loss without necessitating the administration of gut hormone analogues via injection.
AU  - Choudhury,SM
AU  - Tan,TM
AU  - Bloom,SR
DO  - 10.1097/MED.0000000000000216
EP  - 22
PY  - 2016///
SN  - 1752-2978
SP  - 18
TI  - Gastrointestinal hormones and their role in obesity
T2  - Current Opinion in Endocrinology Diabetes and Obesity
UR  - http://dx.doi.org/10.1097/MED.0000000000000216
VL  - 23
ER  -
Download